Immunocore Holdings (IMCR) Accounts Payables (2019 - 2026)

Immunocore Holdings has disclosed Accounts Payables across 8 years of filings, most recently posting $30.2 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $30.2 million, up 3.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.2 million (up 3.61% YoY), and the FY2025 annual result was $24.4 million, down 2.93% from the prior year.
• Accounts Payables came in at $30.2 million for Q1 2026 at Immunocore Holdings, up from $24.4 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $88.1 million in Q4 2022 to a low of $15.5 million in Q1 2024.
• The 5-year median for Accounts Payables is $23.9 million (2025), against an average of $28.8 million.
• Across the five-year window, Accounts Payables sank 79.79% in 2023 and soared 87.76% in 2025, its largest moves.
• Immunocore Holdings' Accounts Payables stood at $88.1 million in 2022, then tumbled by 79.79% to $17.8 million in 2023, then soared by 41.03% to $25.1 million in 2024, then decreased by 2.93% to $24.4 million in 2025, then grew by 23.78% to $30.2 million in 2026.
• The last three Accounts Payables figures came in at $30.2 million (Q1 2026), $24.4 million (Q4 2025), and $23.0 million (Q3 2025), per Business Quant data.